AMRI has signed a definitive agreement to acquire all of the outstanding membership interests of Oso Biopharmaceuticals Manufacturing (OsoBio) for $110 million in cash.
Albuquerque, New Mexico-based OsoBio is recognized as a premier contract manufacturer of highly complex injectable drug products, including sterile liquid, suspension and lyophilized formulations. The acquistion will add to AMRI's sterile manufacturing capabilities, extending the company's position in early stage contract manufacturing to now include OsoBio’s preeminent large-scale commercial production.
OsoBio is expected to continue to operate independently within AMRI’s Drug Product business unit.
Read the AMRI press release